| PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine | 2018 | 659 |
| Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial | Lancet, The | 2014 | 592 |
| Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer | Journal of Clinical Oncology | 2006 | 508 |
| Modified RECIST criteria for assessment of response in malignant pleural mesothelioma | Annals of Oncology | 2004 | 481 |
| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study | Lancet, The | 2020 | 472 |
| Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial | Journal of Clinical Oncology | 2010 | 456 |
| Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer | Lancet, The | 2000 | 455 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study | Annals of Oncology | 2017 | 361 |
| Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Journal of Clinical Oncology | 1999 | 303 |
| Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial | Lancet Oncology, The | 2017 | 266 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma | Oncotarget | 2015 | 238 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study | Lancet, The | 2017 | 225 |
| Resistance training and reduction of treatment side effects in prostate cancer patients | Medicine and Science in Sports and Exercise | 2006 | 217 |
| One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men | Psychoneuroendocrinology | 2004 | 215 |
| A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil | British Journal of Cancer | 2001 | 213 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial | Lancet, The | 2021 | 209 |
| Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer | BJU International | 2008 | 189 |
| Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05) | Radiotherapy and Oncology | 2005 | 189 |
| A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma | British Journal of Cancer | 2002 | 189 |
| Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial | BJU International | 2015 | 176 |
| Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803) | Annals of Oncology | 2013 | 174 |
| [Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 161 |
| Radiotherapy for liver metastases: a review of evidence | International Journal of Radiation Oncology Biology Physics | 2012 | 145 |
| Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation | Prostate Cancer and Prostatic Diseases | 2009 | 145 |
| A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma | British Journal of Cancer | 2004 | 145 |
